Drug Profile


Alternative Names: Paclitaxel-DHA conjugate; Paclitaxel-docosahexaenoic acid conjugate; Taxoprexin

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Luitpold Pharmaceuticals
  • Class Antineoplastics; Paclitaxels; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours

Most Recent Events

  • 08 May 2017 Luitpold Pharmaceuticals terminated a phase II trial in Liver cancer and biliary cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA as the sponsor suspended the development of the drug (IV-infusion) (NCT00422877)
  • 19 Apr 2007 Discontinued - Phase-I/II for Solid tumours in United Kingdom (IV-infusion)
  • 19 Apr 2007 Discontinued - Phase-II for Breast cancer in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top